Urinalysis Interpretation: Microhematuria with Proteinuria
This urinalysis shows microhematuria (1+ blood) with proteinuria (1+ protein) requiring risk-stratified evaluation according to AUA/SUFU guidelines, with the primary concern being exclusion of urothelial malignancy and glomerular disease.
Clinical Significance
The key abnormalities are:
- 1+ blood (microhematuria) - clinically significant finding
- 1+ protein - suggests possible glomerular pathology
- Negative leukocyte esterase and nitrite - makes UTI unlikely despite turbidity
- Normal specific gravity (1.011) and pH 6.0 - within normal range
The turbidity with negative leukocyte esterase is likely from the hematuria and proteinuria itself, not infection 1.
Risk Stratification for Microhematuria
Using the 2020 AUA/SUFU microhematuria guideline 2, you must stratify this patient into low, intermediate, or high-risk categories based on:
Age and smoking history:
- Low risk: Women <50 years or men <40 years who are never smokers or <10 pack-years
- Intermediate risk: Women 50-59 years or men 40-59 years with 10-30 pack-years
- High risk: Any patient ≥60 years or >30 pack-years or history of gross hematuria
Additional urothelial cancer risk factors to assess:
- Occupational exposures (chemicals, dyes, rubber, leather)
- Chronic UTIs or irritative voiding symptoms
- Pelvic radiation history
- Cyclophosphamide exposure
- Aristolochic acid exposure
Required Evaluation Algorithm
1. Immediate Assessment
- Confirm this is true hematuria, not a false positive (the pH 6.0 and normal specific gravity make cell lysis unlikely 3)
- Obtain detailed history for risk factors above
- Repeat urinalysis with microscopy to quantify RBCs/HPF (dipstick alone is insufficient)
2. Microscopic Examination Critical
The presence of dysmorphic RBCs, RBC casts, or significant proteinuria suggests glomerular disease requiring nephrology referral 4. The combination of blood and protein raises this concern.
3. Risk-Based Workup 2
For intermediate to high-risk patients:
- Cystoscopy - to evaluate bladder and urethra for urothelial malignancy
- Upper tract imaging - CT urography preferred (or MR urography if contrast contraindicated)
- Renal function assessment - serum creatinine, eGFR
- Nephrology referral if dysmorphic RBCs, proteinuria >500 mg/day, elevated creatinine, or hypertension present
For low-risk patients:
- May consider repeat urinalysis first
- If persistent (3-10 RBC/HPF on repeat), proceed with shared decision-making regarding full evaluation versus surveillance
4. Proteinuria Workup
Given the concurrent 1+ protein:
- Quantify proteinuria - 24-hour urine collection or spot urine protein-to-creatinine ratio
- If protein >500 mg/day or protein-to-creatinine ratio >0.5, nephrology consultation is warranted 1
- Check serum albumin, creatinine, and consider serologic testing (ANA, complement levels) if glomerular disease suspected
Common Pitfalls to Avoid
Do not dismiss as UTI - The negative leukocyte esterase and nitrite make bacterial UTI unlikely despite turbidity 5
Do not attribute to menstrual contamination without confirmation - If female patient, timing relative to menses matters, but persistent hematuria requires evaluation
Do not delay evaluation in high-risk patients - Microhematuria may precede bladder cancer diagnosis by years 4
Do not ignore the proteinuria - The combination of hematuria and proteinuria increases likelihood of glomerular pathology requiring different management than isolated hematuria
Follow-up Protocol
If initial evaluation is negative 2, 4:
- Annual urinalysis for persistent microhematuria
- Repeat full evaluation in 3-5 years if microhematuria persists and patient has risk factors
- Immediate re-evaluation if gross hematuria develops, substantial increase in degree of microhematuria, or new urologic symptoms appear
The specific gravity of 1.011 is adequate for interpretation and does not significantly affect the accuracy of these findings 6.